We previously reported that a deficiency in the vasopressin V1a receptor (V1aR) results in type 4 renal tubular acidosis, which suggests that vasopressin exerts direct effects on the physiological actions of aldosterone. We investigated the role of vasopressin for nucleocytoplasmic transport of mineralocorticoid receptor (MR) in the intercalated cells. Vasopressin V1aR-deficient (V1aR Ϫ/Ϫ ) mice showed largely decreased expression of MR and 11␤-hydroxysteroid dehydrogenase type 2 (11␤HSD2) in the medulla of the kidney, which was partially ameliorated by fludrocortisone treatment. The incubation of IN-IC cells, an intercalated cell line established from temperature-sensitive SV40 large T antigen-expressing rats, with aldosterone or vasopressin increased the nuclear-tocytoplasmic ratio of the MR from 11.2 to 47.2% and from 18.7 to 61.2%, respectively, in 30 min without any changes in MR expression from the whole cell extract. The immunohistochemistry analysis of the IN-IC cells revealed the nuclear accumulation of MRs after a 30-min incubation with aldosterone or vasopressin. These effects were accompanied by an increase in regulator of chromosome condensation-1 (RCC-1) due to aldosterone and a decrease in Ran GTPaseactivating protein 1 (Ran Gap1) due to vasopressin. RNA interference against V1aR abolished the nuclear accumulation of MR induced by aldosterone or vasopressin. Vasopressin increased PKC␣ and -␤1 expression, and aldosterone increased PKC␦ and -expression, but these effects were abolished with a V1aR knockdown. These results suggest that vasopressin directly regulates the nucleocytoplasmic transport of MRs via the V1aR in the intercalated cells of the collecting ducts.
important roles for organ damage in kidney and heart (45, 42) . Vasopressin modulates sodium and water transport via two types of receptors; vasopressin V2 and V1a receptors (V2R and V1aR, respectively; Refs. 5, 6, 8, 13, 21, 37) . While V2R mediates the antidiuretic effects of vasopressin, V1aR has important roles for acid-base regulation (5, 6, 21) . The distribution of V1aR in the glomerulus, thick ascending limbs, and the collecting ducts was very similar to that of V2R (9, 15, 20, 39, 40) . V2R is localized on basolateral membrane, while V1aR has been suggested to be on luminal membrane in the renal tubules. We and others (2, 32, 33) have demonstrated that stimulation of luminal V1aR in the collecting ducts downregulates the basolateral V2R-induced antinatriuretic effects of vasopressin. However, the role of V1aR for electrolyte/water transport and acid-base regulation has been considered negligible (6, 21) .
The renin-angiotensin-aldosterone system (RAS) participates in volume and acid-base regulation in the kidney. Aldosterone exerts its physiological effects through nongenomic actions of the MR in the cytoplasm and possibly in phospholipid membrane and also through genomic actions of the MR in the nucleus in the distal nephron (1, 42, 44, 45) . The nucleocytoplasmic transport of MRs is induced by aldosterone and is regulated by molecular chaperones, Ran cycle, immunophilins, and dynein that interact with cytoskeleton network (10, 11, 12, 23, 24, 27, 28, 35, 38, 46) . In contrast, vasopressin participates in osmo-and acid-base regulation by controlling water, sodium, and bicarbonate reabsorption in the thick ascending limbs and the collecting ducts (6, 8, 13, 21, 37) . Although cross-talk between RAS and vasopressin system has been demonstrated, most of these cross talks are indirect (19) . We (3, 4, 22, 25) previously reported that a deficiency in the V1aR results in hyporeninemic hypoaldosteronism and a type 4 renal tubular acidosis, which is characterized by reduced renal function, metabolic acidosis, and hyperkalemia. These data suggest that V1aRs are essential for the acid-base regulation mediated by aldosterone (22) , suggesting a cross talk between RAS and vasopressin system.
V1aR is a transmembrane protein coupled with G q/11 (30) , whereas the MR is a nuclear receptor. MRs are present mainly in the cytoplasm of cells in the thick ascending limbs and collecting ducts, and V1aR is thought to be present at the luminal membrane of the intercalated cells of the colleting ducts (1, 6, 21, 22, 43) . The new IN-IC cell line, established from temperature-sensitive SV40 large T antigen-expressing rats (47) (FACT, Sendai, Japan), possesses the characteristics of intercalated cells since it expresses V1aR and acid-baserelated transporters but lacks epithelial sodium channels, V2R, and aquaporin-2 (22) . We (22) previously showed that vasopressin and aldosterone regulate protein abundance of acidbase related transporters through the V1aR in IN-IC cells. Interestingly, IN-IC cells express the MR and 11␤-hydroxysteroid dehydrogenase type 2(11␤HSD2), which has a key role for aldosterone action. We therefore investigated the regulation of aldosterone-induced nucleocytoplasmic transport of MR by vasopressin in these IN-IC cells.
METHODS
Animal and cell culture. V1aR knockout mice and the intercalated cell line (IN-IC cells) were generated as previously described (3, 4, 22, 25 ; SigmaAldrich) was intraperitoneally injected to both wild and V1aR Ϫ/Ϫ mice for 3 days before the renal medulla was taken. The knockdown of the V1aR gene was performed as previously described (22) . The IN-IC cells were incubated at 33°C in DMEM/F12 medium (Life Technologies), 10% FBS, 10 g/ml transferrin, 1 g/ml insulin, 10 ng/ml EGF, 0.5 g/ml hydrocortisone, 6.5 ng/ml Triiodo-Tyronine, and 1% penicillin/streptomycin.
Western blot. Western blot analysis was performed as previously described (4, 22, 33) . For SDS-PAGE, 10 -50 g of protein from the kidney medulla or IN-IC cells were used. A fraction from the nucleus and cytoplasm of the IN-IC cells were obtained using a kit from Thermo Scientific (NE-PER nuclear and cytoplasmic extraction kit). To reduce the contamination of the cytoplasmic fraction in the nuclear fraction, a washing step for the nuclear fraction using cytoplasmic extraction reagent buffer was included in the protocol, as described by the manufacturer. The antibodies against ␣ tubulin and Brg-1 were purchased from Santa Cruz (sc-69969 and 17796, respectively) and were used to confirm the cytoplasmic and nuclear fractions, respectively. The nuclear-to-cytoplasmic (N/C) ratio was calculated by taking a ratio of band intensities revised by protein amount of nuclear and cytoplasmic fractions.
The antibodies against the MR and 11␤HSD2 were a kind gift from Dr. C. Gomez-Sanchez (University of Mississippi; Refs. 17, 18) . The antibodies against PKC (␣, ␤ 1, ␦, and ), importin 7, Nup50, regulator of chromosome condensation-1 (RCC-1), and Ran GTPase-activating protein 1 (Ran Gap1) and Ran were purchased from Santa Cruz (sc-8393, 8049, 8402, 17781, 271701, 133859, 55559, 28322, and 271376, respectively). Primary and secondary antibodies were used at the dilution of 5,000 -10,000 and 100,000 -200,000, respectively. The detection of the bands was performed by Enhanced Chemiluminescence Advance (GE Healthcare) using LAS-4000 mini (Fuji Film) in the Research Facility for Common Use in Hyogo College of Medicine.
Immunohistochemistry. IN-IC cells were incubated in a hydrocortisone-free abovementioned medium for 24 h at 33°C before the addition of V1aR-small interfering (si)RNA and for subsequent 48 h before the addition of aldosterone or vasopressin. After the addition and incubation with aldosterone (10 Ϫ6 M) or vasopressin (10 Ϫ7 M), the cells were fixed with 1% paraformaldehyde for 60 min at room temperature. After the cells were imbedded in paraffin, the sections were cut, rinsed and treated with an EDTA solution (pH 9, Nichirei No. 415211, Tokyo, Japan) at 95°C for 10 min for the antigen retrieval heating. The primary antibody against the MR was used at a 1:50 dilution of MRN 1D5 from Dr. Gomez-Sanchez (16, 17 
RESULTS
Vasopressin V1aR is required for nucleocytoplasmic transport of MR. Aldosterone (fludrocortisone, 25 mg·kg Ϫ1 ·day Ϫ1 ) stimulated the expression of the MR and 11␤ HSD2 in the kidney, and these effects were largely decreased in the vasopressin V1aR-deficient mice (Fig. 1, A and B) . In the IN-IC cells, the aldosterone dose dependently increased the expression of the MR with 24 h but not with 30 min, which suggests that the genomic effects of aldosterone require 24 h to occur ( Vasopressin (10 Ϫ7 M) also increased the N/C ratio of MRs from 18.7 Ϯ 9.4 to 61.2 Ϯ 9.8% (P Ͻ 0.05; n ϭ 6) after 30 min of incubation, and these effects were abolished by the knockdown of V1aR ( Fig. 2C ; 17.4 Ϯ 3.8 and 23.1 Ϯ 3.1 in vehicle plus siRNA and vasopressin plus siRNA, respectively; P Ͻ 0.05; n ϭ 6).
The localization of MRs in IN-IC cells was also examined using immunohistochemistry. MRs were observed mainly in the cytoplasm but were also found at low levels in the nucleus under basal conditions (Fig. 2D) . A 30-min incubation with aldosterone largely increased the nuclear accumulation of MRs, and a V1aR knockdown abolished the aldosteroneinduced nuclear accumulation of MRs. Vasopressin also induced the nuclear accumulation of MRs, and V1aR knockdown abolished this effect. The nuclear accumulation of MRs induced by aldosterone or vasopressin was sustained for 24 h following the incubation, and the effect of the V1aR knockdown on the nuclear accumulation of MR was also sustained at 24 h (Fig. 2D) .
Different effects of aldosterone and vasopressin on Ran cycle. We next examined the cytoplasmic and nuclear expression of nuclear transport chaperones in IN-IC cells. The nuclear transport of the MR has been suggested to be accompanied by members of the importin family (12, 23, 38, 46) . RCC-1 and Ran Gap1 are known to regulate Ran-GTP and Ran-GDP, respectively, which drive importin-dependent nuclear transport (11, 12, 24, 27, 28 Ran was detected mainly in the cytoplasm but also at low levels in the nucleus (Fig. 3, A and  B) . The effects of 30-min aldosterone and vasopressin treatments on the expression of nuclear transport chaperones were examined in the whole cell extracts (Fig. 3, G and H) , and very little expression of the SUMOylated form of Ran Gap1 (90 kDa) and no effects of the aldosterone and vasopressin treatments were demonstrated. Aldosterone and vasopressin did not affect the expression of the MR, RCC-1, or Ran Gap1. Aldosterone, but not vasopressin, increased the expression of Ran ( Ϫ6 M aldosterone compared with vehicle, respectively; n ϭ 4; Fig. 3G ), which is consistent with the increase in the nuclear levels of RCC-1 (Fig. 3C) .
Different stimulation of PKC pathways by vasopressin and aldosterone.
We next examined the effects of aldosterone and vasopressin on PKC expression, as V1aR is a G q/11 -coupled receptor and aldosterone is suggested to stimulate PKC path- (Fig. 4, A and C) . However, aldosterone did not increase the expression of PKC␣ and -␤ 1 (Fig. 4, B and D) . Furthermore, vasopressin treatment did not alter the expression of PKC␦ or - (Fig. 4, E and G) , whereas aldosterone treatment increased the expression of both of these subtypes (Fig. 4, F and H) . These data suggest that vasopressin stimulates conventional PKC pathways, whereas aldosterone stimulates atypical or novel PKC pathways, indicating that V1aR is not a membrane-bound receptor of aldosterone.
DISCUSSION
Our data have provided the first evidence to indicate that vasopressin regulates the nucleocytoplasmic trafficking of the MR through the use of V1aR. Vasopressin and aldosterone participate in kidney osmoregulation and volume regulation, respectively, and have been postulated to be individually regulated. Therefore, it is surprising that the MR, an aldosterone receptor, is regulated not only by aldosterone but also by vasopressin and that the presence of V1aR is essential for aldosterone's action. Another interesting finding is that aldosterone and vasopressin work via the basolateral and luminal sides of the intercalated cells, respectively. Although V1aR at the luminal side negatively regulates the sodium and water transport that is activated by V2R at the basolateral side in principal cells, luminal vasopressin action constitutes the partial inhibition of the basolateral action of vasopressin (33) . However, our current results suggest that luminal vasopressin modulates the effect of basolateral aldosterone in terms of the genomic and nongenomic regulation of the MR. Because aldosterone causes an accumulation of water and sodium in the body, luminal vasopressin, as a marker of urine flow, may be required for the precise action of aldosterone.
Our data show that vasopressin stimulates conventional PKC pathways but not atypical or novel PKC pathways, whereas aldosterone stimulates atypical or novel PKC pathways but not conventional PKC pathways, suggesting the stimulation of different PKC pathways by vasopressin and aldosterone. Activation of PKC ␣ by aldosterone has been shown using a cell line from the principal cells of the collecting duct rather than intercalated cells (26) . Thomas and Harvey (42) have suggested that aldosterone activates the novel PKC pathway, which is compatible with our data. PKC stimulation by luminal vasopressin is mediated by V1aR, and the stimulation of PKC by aldosterone may be caused by the membrane-localized not MR but EGF receptor (18) . G-protein-coupled receptor 30 has also been suggested as a possible membrane-bound aldosterone receptor (14) . Different stimulation of PKC pathways by vasopressin and aldosterone and different intracellular localization of membrane-bound aldosterone receptor and V1aR in basolateral and luminal membrane, respectively, suggests that V1aR is not a membrane-bound receptor of aldosterone. Although the role of PKC in the nucleocytoplasmic transport of MR is not known, the stimulation of distinct PKC pathways by vasopressin and aldosterone implies their some participation in the regulation of the nucleocytoplasmic transport of MRs. As Ran is a small G protein, the stimulation of a small G protein by aldosterone and vasopressin is more relevant for the nucleocytoplasmic transport of MR.
Little is known about the mechanisms of MR nucleocytoplasmic transport in intercalated cells. The presence of the MR in the intercalated cells was first confirmed by our previous report (22, 31) , and our present data suggest that aldosterone and vasopressin regulate RCC-1 and Ran Gap-1 activity to stimulate the nucleocytoplasmic transport of the MR (Fig. 5) . The stimulation of RCC-1 by aldosterone and the inhibition of Ran Gap-1 by vasopressin causes a rapid increase in Ran-GTP in the nucleus, which facilitate the transport of MR into the nucleus. Molecular chaperones, immunophilinsm, and dynein are involved in the movement of MR into the nuclei by interacting with cytoskeleton network (10 -12, 23, 24, 27, 28, 35, 38, 46) . Molecular chaperones, such as importin 7 and Nup 50, which were present only in the cytoplasm, were not altered by aldosterone or vasopressin treatment. The lack of V1aR may influence cytoskeleton network and subsequently nucleocytoplasic transport of MR, although we need further experiments to confirm the possibility.
The dose of fludrocortisone, 25 mg/kg, is very high, suggesting the possibility of glucocorticoid as well as mineralocorticoid action. However, the expression of the key enzyme for aldosterone action, 11␤HSD2, is largely stimulated in wild-type mice, suggesting the blockade of glucocorticoid action by administered fludrocortisone. We suspect the overdose of fludrocortisone have reached the plateau. Since stim- Fig. 3 . A: effects of aldosterone on nuclear transport chaperones and Ran abundance in the cytoplasm and nucleus. Administration of aldosterone did not change the abundance of importin 7 and Nup 50 in the cytoplasm or nucleus but increased the nuclear abundance of Ran. B: effects of vasopressin on nuclear transport chaperones and Ran abundance in the cytoplasm and nucleus. Administration of vasopressin did not change the expression of importin 7 or Nup 50 in the cytoplasm or the nuclear abundance of Ran. C: effects of aldosterone on regulator of chromosome condensation-1 (RCC-1) abundance in the cytoplasm and nucleus. RCC-1 was observed only in the nucleus (a band with a slightly larger molecular weight was seen in the cytoplasm). Administration of aldosterone increased RCC-1 abundance in the nucleus, and the V1aR knockdown abolished the effect. *P Ͻ 0.05 vs. aldosterone (Ϫ) and siRNA (Ϫ); n ϭ 6. D: effects of vasopressin on the abundance of RCC-1 in the cytoplasm and nucleus. Vasopressin did not change the RCC-1 abundance in the nucleus. E: effects of aldosterone on the abundance of Ran GTPase-activating protein 1 (Ran Gap1) in the cytoplasm and nucleus. In the cytoplasm and nucleus, 70-kDa Ran Gap1 was observed, and the administration of aldosterone did not alter Ran Gap1 abundance. F: effects of vasopressin on Ran Gap1 abundance in the cytoplasm and nucleus. Administration of vasopressin increased the abundance of 70-and 90-kDa Ran Gap1 in the nucleus, and V1aR knockdown abolished this effect. Specificity of the antibody was confirmed using HEK293T cell lysate, which is known to expresses Ran Gap1, as shown in the first lane on the left. Graph represents the cytoplasmic /nuclear-to-cytoplasmic (C/NϩC) ratio. Vasopressin decreased the abundance of 70-kDa Ran Gap1 in the cytoplasm. *P Ͻ 0. apeutic usefulness of V1aR regulation have been recently suggested (7, 34) .
In conclusion, our findings indicate that luminal vasopressin regulates the nucleocytoplasmic transport of MRs as well as aldosterone at the basolateral side. Moreover, a dual action system may be necessary for the complete action of aldosterone. Aldosterone increased the nuclear RCC-1 abundance and subsequently increased that of Ran, which led to the nuclear transport of the MR. However, vasopressin decreased the cytoplasmic Ran Gap1 abundance, which led the MR abundance in the nucleus. Importin 7 and Nup 50 were not altered by aldosterone or vasopressin treatment.
